Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Asthma is a condition that makes breathing difficult due to swelling and tightening of the airways. It is caused by a combination of genetic, environmental, and lifestyle factors, such as a family ...

It’s common to have a food allergy if you have asthma. Eating dairy cannot cause asthma, but you may experience an asthma attack if you have a dairy allergy and consume dairy. Asthma is a ...

A 12-month interim analysis of the AGILE Phase III open-label extension study confirms that twice-yearly depemokimab, an ultra-long-acting anti-IL-5 biologic, maintains a favorable safety and efficacy ...

A new asthma treatment, depemokimab, has shown promise in reducing exacerbations while maintaining a strong safety profile, according to findings presented at the 2025 American Academy of Allergy ...

Breathing cold air during winter can make asthma symptoms worse. Working with your doctor to develop an effective asthma action plan and following it is key to effective treatment. If you have ...

SAN DIEGO — Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically significant exacerbations, according to a poster abstract ...

Her brother has confirmed that the YouTuber died from an asthma attack in her sleep. “There’s a spread of misinformation online, stating different things based on speculation,” he said.

A Prescription Drug User Fee Act target date of December 16, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

Medications that target inflammation, such as immunotherapy and steroids, treat allergic asthma, a common type of asthma. Identifying triggers and avoiding exposure to substances that exacerbate ...

SWIFT-1 and -2 showed depemokimab reduced exacerbation and hospitalization rates as an add-on therapy for patients with asthma with type 2 inflammation versus placebo. ANCHOR-1 and 2 showed early ...